{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:32:18Z","timestamp":1782919938756,"version":"3.54.5"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.phrs.2018.04.020","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T15:07:01Z","timestamp":1524668821000},"page":"35-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.04.020_bib0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2018.04.020_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2018.04.020_bib0020","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.04.020_bib0025","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/febs.13600","article-title":"The extended human PTPome: a growing tyrosine phosphatase family","volume":"283","author":"Alonso","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2018.04.020_bib0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/320415a0","article-title":"A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family","volume":"320","author":"Besmer","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.04.020_bib0035","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand","volume":"6","author":"Yarden","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.04.020_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase-The stem cell factor receptor","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0045","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2018.04.020_bib0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V91.4.1101","article-title":"c-kit ligand and Flt3 ligand: stem\/progenitor cell factors with overlapping yet distinct activities","volume":"91","author":"Lyman","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.04.020_bib0055","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1073\/pnas.93.5.1808","article-title":"Steel mutant mice are deficient in hippocampal learning but not long-term potentiation","volume":"5","author":"Motro","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0060","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/00001756-200004270-00004","article-title":"Defects in sensory nerve numbers and growth in mutant Kit and Steel mice","volume":"11","author":"Lourenssen","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.phrs.2018.04.020_bib0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.bi.62.070193.002321","article-title":"Signaling by receptor tyrosine kinases","volume":"62","author":"Fantl","year":"1993","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.phrs.2018.04.020_bib0070","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.04.020_bib0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase-The stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0080","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1346-8138.2012.01583.x","article-title":"Piebaldism","volume":"40","author":"Oiso","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0085","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.04.020_bib0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc1434","article-title":"Switching on kinases: oncogenic activation of BRAF and the PDGFR family","volume":"4","author":"Dibb","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0100","first-page":"686","article-title":"Mastocytosis: a disease of the hematopoietic stem cell","volume":"105","author":"Horny","year":"2008","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.phrs.2018.04.020_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.04.020_bib0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yasu.2014.05.014","article-title":"Gastrointestinal stromal tumors: who should get imatinib and for how long?","volume":"48","author":"Balachandran","year":"2014","journal-title":"Adv. Surg."},{"key":"10.1016\/j.phrs.2018.04.020_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2016.11.011","article-title":"GEIS guidelines for gastrointestinal sarcomas (GIST)","volume":"55","author":"Poveda","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2018.04.020_bib0130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/14737140.2017.1400386","article-title":"New targets and therapies for gastrointestinal stromal tumors","volume":"17","author":"Wozniak","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.phrs.2018.04.020_bib0135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"Casali","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0140","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.020_bib0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.020_bib0150","first-page":"189","article-title":"Gastrointestinal stromal tumor","volume":"3","author":"Zhao","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11523-017-0490-9","article-title":"Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors","volume":"12","author":"Serrano","year":"2017","journal-title":"Target Oncol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0160","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.04.020_bib0165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1365-2133.2001.04123.x","article-title":"Mastocytosis: recent advances in defining the disease","volume":"144","author":"Hartmann","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ajh.23821","article-title":"Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy","volume":"89","author":"Solh","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0175","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.phrs.2018.04.020_bib0180","first-page":"5941","article-title":"New drug combination strategies in melanoma: current status and future directions","volume":"37","author":"Najem","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0185","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cncr.30593","article-title":"Somatic driver mutations in melanoma","volume":"123","author":"Reddy","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0190","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0195","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2018.04.020_bib0200","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.04.020_bib0205","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.04.020_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0215","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1021\/ja312237q","article-title":"Phosphoryl transfer by protein kinase A is captured in a crystal lattice","volume":"135","author":"Bastidas","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2018.04.020_bib0220","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0225","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2018.04.020_bib0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2018.04.020_bib0235","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.04.020_bib0240","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jb\/mvq015","article-title":"Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance","volume":"147","author":"DiNitto","year":"2010","journal-title":"J. Biochem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cell.2007.05.055","article-title":"Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor","volume":"130","author":"Yuzawa","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.04.020_bib0250","doi-asserted-by":"crossref","first-page":"E4784","DOI":"10.1073\/pnas.1610179113","article-title":"Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition","volume":"113","author":"Shi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0255","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2018.04.020_bib0260","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/sj.onc.1202929","article-title":"Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor\/c-kit mediated activation of the Ras\/MAP kinase pathway and c-fos induction","volume":"18","author":"Lennartsson","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2018.04.020_bib0265","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2017.03.004","article-title":"Targeting tyrosine phosphatases: time to end the stigma","volume":"38","author":"Stanford","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2018.04.020_bib0270","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.03.012","article-title":"Src kinase regulation by phosphorylation and dephosphorylation","volume":"331","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0280","series-title":"Reference Module in Life Sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2018.04.020_bib0285","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumor","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.020_bib0290","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Ten Eyck LF: Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0295","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0310","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0325","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0330","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0350","doi-asserted-by":"crossref","first-page":"e1001690","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0360","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0365","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0370","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0375","doi-asserted-by":"crossref","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-kit product complex reveals the basis for kinase transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0380","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0385","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0390","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","article-title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients","volume":"20","author":"Garner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0395","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1016\/j.bmc.2016.07.059","article-title":"The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: implications for drug design","volume":"24","author":"Kissova","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0400","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.phrs.2018.04.020_bib0405","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0410","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the gatekeeper door: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0420","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2018.04.020_bib0425","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0430","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0435","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0440","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0445","first-page":"1115","article-title":"Juxtamembrane mutant V560G Kit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816V Kit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.04.020_bib0450","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0455","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2003.08.055","article-title":"STI-571: an anticancer protein-tyrosine kinase inhibitor","volume":"309","author":"Roskoski","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0460","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.04.020_bib0465","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.04.020_bib0470","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0475","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0480","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0485","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2147\/DDDT.S109640","article-title":"Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy","volume":"11","author":"Bellesoeur","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2018.04.020_bib0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0495","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 1 Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0500","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.04.020_bib0505","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/phar.2076","article-title":"Cabozantinib: a multitargeted oral tyrosine kinase inhibitor","volume":"38","author":"Markowitz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2018.04.020_bib0510","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0515","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KIT D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.04.020_bib0520","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0525","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1124\/mol.105.020172","article-title":"Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)","volume":"69","author":"Chen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2018.04.020_bib0530","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/10428194.2011.555890","article-title":"The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms","volume":"52","author":"Amrein","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2018.04.020_bib0535","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.22681","article-title":"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition","volume":"121","author":"Antonescu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0540","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/13543784.2013.740010","article-title":"Therapeutic targeting of c-KIT in cancer","volume":"22","author":"Ashman","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2018.04.020_bib0545","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0550","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2018.04.020_bib0555","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43\u20139006: preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2018.04.020_bib0560","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","article-title":"Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment","volume":"41","author":"Strumberg","year":"2005","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.phrs.2018.04.020_bib0565","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-07-0484","article-title":"Sorafenib inhibits the imatinib-resistant KITT670Igatekeeper mutation in gastrointestinal stromal tumor","volume":"13","author":"Guo","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0570","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2018.04.020_bib0575","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2018.04.020_bib0580","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.04.020_bib0585","doi-asserted-by":"crossref","first-page":"55827","DOI":"10.1074\/jbc.M409792200","article-title":"A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase","volume":"279","author":"Atwell","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.04.020_bib0590","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.04.020_bib0595","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2017.09.020","article-title":"Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors","volume":"127","author":"Savi","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0600","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.phrs.2017.06.007","article-title":"Chasing c-Kit through the heart: taking a broader view","volume":"127","author":"Gude","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.020_bib0605","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2018.04.020_bib0610","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2018.04.020_bib0615","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818305991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818305991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:54:22Z","timestamp":1760910862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818305991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":123,"alternative-id":["S1043661818305991"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.020","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}